Bayer HealthCare announced that the FDA has approved Kogenate FS Antihemophilic Factor to reduce the frequency of bleeding episodes and the risk of joint damage in patients up to age 16 with severe hemophilia A. "The FDA approval of Kogenate FS as the first factor VIII treatment product in the U.S. to be used to replenish factor VIII levels in a prophylactic manner marks a significant milestone in the care of patients, especially young children, with hemophilia A," said Craig Kessler, M.D., Georgetown University Hospital and Chair, MASAC. Release [1]
Links:
[1] http://www.fiercebiotech.com/press-releases/fda-approves-bayer-healthcares-kogenate-r-fs-treatment-routine-prophylaxis-children-0